These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25686729)

  • 1. Azithromycin use in patients with cystic fibrosis.
    Principi N; Blasi F; Esposito S
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1071-9. PubMed ID: 25686729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Azithromycin therapy in cystic fibrosis].
    Máiz Carro L; Cantón Moreno R
    Med Clin (Barc); 2004 Mar; 122(8):311-6. PubMed ID: 15030744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
    JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials.
    Mayer-Hamblett N; Saiman L; Lands LC; Anstead M; Rosenfeld M; Kloster M; Fisher L; Ratjen F
    Contemp Clin Trials; 2013 Sep; 36(1):99-105. PubMed ID: 23770109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term azithromycin therapy in patients with cystic fibrosis.
    Emiralioğlu N; Öztürk Z; Yalçın E; Doğru D; Özçelik U; Kiper N
    Turk J Pediatr; 2016; 58(1):34-40. PubMed ID: 27922234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
    Saiman L; Mayer-Hamblett N; Campbell P; Marshall BC;
    Am J Respir Crit Care Med; 2005 Oct; 172(8):1008-12. PubMed ID: 16040785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role Of Long-Term Intermittent Use Of Oral Azithromycin On Pulmonary Exacerbations In Cystic Fibrosis Children.
    Aziz DA; Shahid S; Iftikhar H; Mir F
    J Ayub Med Coll Abbottabad; 2020; 32(4):429-434. PubMed ID: 33225638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.
    Pirzada OM; McGaw J; Taylor CJ; Everard ML
    J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy.
    Oliver A
    Int J Med Microbiol; 2010 Dec; 300(8):563-72. PubMed ID: 20837399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
    Hansen CR; Pressler T; Koch C; Høiby N
    J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Macrolides, Pseudomonas aeruginosa and cystic fibrosis].
    Guillot M; Amiour M; El Hachem C; Harchaoui S; Ribault V; Paris C
    Arch Pediatr; 2006 Oct; 13 Suppl 1():S48-50. PubMed ID: 17370396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Döring G
    Int J Med Microbiol; 2010 Dec; 300(8):573-7. PubMed ID: 20940108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic fibrosis infections: treatment strategies and prospects.
    George AM; Jones PM; Middleton PG
    FEMS Microbiol Lett; 2009 Nov; 300(2):153-64. PubMed ID: 19674113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
    Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS
    J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.
    Clement A; Tamalet A; Leroux E; Ravilly S; Fauroux B; Jais JP
    Thorax; 2006 Oct; 61(10):895-902. PubMed ID: 16809416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azithromycin for improving pulmonary function in cystic fibrosis.
    Carr RR; Nahata MC
    Ann Pharmacother; 2004 Sep; 38(9):1520-4. PubMed ID: 15213312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
    Parkins MD; Elborn JS
    J Antimicrob Chemother; 2010 Sep; 65(9):1853-61. PubMed ID: 20605846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review.
    Cai Y; Chai D; Wang R; Bai N; Liang BB; Liu Y
    J Antimicrob Chemother; 2011 May; 66(5):968-78. PubMed ID: 21393178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.